Cystatin C as a Marker of Progressing Cardiovascular Events during Coronary Heart Disease
The role of cystatin C, an inhibitor of cysteine proteases, as an alternative and potent predictor of acute cardiovascular events in coronary heart disease (CHD) patients was examined and compared to that of other markers of cardiorenal abnormalities. The patients with CHD demonstrated elevated serum cystatin C, especially in cases with serious risk of cardiovascular complications. In comparison with other indicators of cardiorenal dysfunction, cystatin C can be viewed as an alternative predictor of cardiovascular complications, although its sensitivity is inferior to that of high-sensitivity C-reactive protein and natriuretic peptide.
Key Wordscystatin C coronary heart disease biochemical markers clinical study
Unable to display preview. Download preview PDF.
- 1.Cherkanova MS, Korolenko TA, Yu Brawe I, Gerasimova TP. Effect of statins on activity of matrix metalloproteases and serum concentration of cystatin C in patients with various risk of development of ischemic heart disease and in patients after coronary artery bypass surgery. Kardiologiya. 2012;52(2):23-28. Russian.Google Scholar
- 4.Grubb A, Blirup-Jensen S, Lindström V, Schmidt C, Althaus H, Zegers I; IFCC Working Group on Standardisation of Cystatin C (WG-SCC). First certified reference material for cystatin C in human serum ERM-DA471/IFCC. Clin. Chem. Lab. Med. 2010;48(11):1619-1621.Google Scholar
- 5.Korolenko TA, Cherkanova MS, Gashenko EA, Johnston TP, Bravve IY. Cystatin C, atherosclerosis and lipid-lowering therapy by statins. Cystatins: Protease Inhibitors, Biomarkers and Immunomodulators. Cohen JB, Rysek LP, eds. New York, 2011. P. 187-204.Google Scholar
- 6.Korolenko T, Cherkanova M, Gerasimova T, Korolenko Ts. Matrix metalloproteases, chitotriosidase and cystatin C in long-term study in patients after cardiosurgery. New Insights into Mechanisms and Management of Heart Disease. Kimchi A, ed. Vancouver, 2014. P. 57-86.Google Scholar